William Lewis Sells 4,096 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 4,096 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $173.33, for a total transaction of $709,959.68. Following the completion of the transaction, the chief executive officer directly owned 320,987 shares in the company, valued at $55,636,676.71. This represents a 1.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Lewis also recently made the following trade(s):

• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $412,639.99.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Performance

INSM traded down $5.73 during trading on Thursday, reaching $170.27. 2,588,589 shares of the company were exchanged, compared to its average volume of 2,142,398. The stock has a market cap of $36.31 billion, a P/E ratio of -27.51 and a beta of 1.08. The firm has a 50 day moving average of $190.79 and a 200 day moving average of $151.24. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business’s quarterly revenue was up 52.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.27) earnings per share. On average, sell-side analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Darwin Global Management Ltd. raised its position in Insmed by 5.8% in the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock worth $2,897,797,000 after acquiring an additional 1,112,824 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after purchasing an additional 2,291,328 shares during the last quarter. Capital International Investors raised its holdings in shares of Insmed by 1.0% in the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after purchasing an additional 74,994 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares in the last quarter. Finally, Duquesne Family Office LLC lifted its stake in Insmed by 3.0% during the third quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock valued at $348,999,000 after purchasing an additional 70,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on INSM shares. Truist Financial assumed coverage on shares of Insmed in a research note on Friday, December 19th. They issued a “buy” rating and a $202.00 price target on the stock. Evercore ISI reissued an “outperform” rating and issued a $180.00 price objective on shares of Insmed in a report on Wednesday, October 1st. Redburn Partners set a $263.00 target price on Insmed in a research report on Thursday, December 4th. UBS Group cut their target price on Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Bank of America increased their price target on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.64.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.